The object of the day was to outline the national and European regulations and basic legal requirements that affect the development and production of such therapies, as well as their transfer, distribution and use in the public realm. After an introduction by IBEC\u2019s director Josep A. Planell, speakers from the Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS) and from CIBER-BBN research groups addressed a range of topics and questions including \u201cWill advanced therapies take the place of transplants?\u201d and \u201cThe regulatory aspects of research into pluripotent stem cells: legislation and ethics\u201d.<\/p>\n
\u201cIt was really useful to meet the people from the regulatory bodies,\u201d commented IBEC group leader \u00c1ngel Raya, who\u2019s head of the Control of stem cell potency lab. \u201cThey can be helpful with setting up clinical trials and advising on protection and commercialisation, so it was good to be able to get to know them face-to-face. I also found out that there are hotlines devoted to helping researchers with the process, which I didn\u2019t realise before.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"
More than 60 researchers, medical professionals, company representatives and other interested participants from the health sector came to IBEC on 5 October for a CIBER-BBN conference, \u201cInvestigaci\u00f3n y desarrollo de terapias avanzadas: introducci\u00f3n en aspectos regulatorios\u201d (Research and development of Advanced Therapies: an introduction to regulatory aspects). <\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[],"post_formats":[],"class_list":["post-5363","post","type-post","status-publish","format-standard","hentry","category-institutional-news"],"yoast_head":"\n